Balkees Abderrahman is Postdoctoral Fellow, Breast Medical Oncology, University of Texas MD Anderson Cancer Center, 1500 Holcombe Blvd. Unit #1354, Houston, TX 77030, United States.
Chemoprevention in British women is inadequateSubscription
We write to outline our concerns that breast cancer prevention strategies are not being implemented to their fullest potential in the UK. Breast cancer is the most common female cancer and the second leading cause of death in women in the UK. According to Cancer Research UK, there were more than 55,000 new cases of breast cancer and more than 11,000 deaths from breast cancer in 2014
Breast cancer prevention trumps cureSubscription
Breast cancer is the most prevalent female cancer and is estimated to increase by 50% by 2030 compared to the incidence in 2011. The decision by the National Institute for Health and Care Excellence (NICE), the UK health technology appraiser, to recommend the use of preventive medicines, which are known to decrease the risk of developing breast cancer, is a welcome advance in public health. These medicines have been rigorously studied, and tens of thousands of women who at high risk of
Since the dawn of hormonal replacement therapy — now known as menopausal hormone therapy — there have been conflicting reports about its risks and safety. A thorough examination of the evidence suggests it can be used safely in menopausal women.